Loading
A phase 2 trial of L19IL2 in basal cell carcinoma, run by Philogen S.p.A., now recruiting.
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT07227350 by Philogen S.p.A., with 180 participants planned, started 2026-06-01 and due to reach its primary completion in 2031-02. Interventions recorded: L19IL2, L19TNF and L19IL2/L19TNF.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Philogen S.p.A. and the tag pipeline.
Shares Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/